Over the past 12 months, $EIKN has been discussed by 2 distinct FinTwit voices, with 6 total mentions concentrated between February 2-6, 2026. Jacob Plieth (@jacobplieth) accounts for 5 of those mentions, making him the most active voice discussing the biotech company, while Adam Feuerstein (@adamfeuerstein) contributed 1 mention. The discussion centered on the company's IPO pricing and valuation metrics relative to investor returns.

The initial mention of $EIKN appeared on February 2, 2026. Subsequent discussion focused on the IPO pricing at $18 per share with a $972 million market cap to raise $381 million, with Jacob Plieth noting the stock trading 15% below its issue price and 55% below average venture capital investment levels. Adam Feuerstein's mention on February 5 was brief, simply stating "Let's blame $EIKN for this" without elaborating on specific concerns.